---
title: "KANGO SUJAY — Ownership Dossier"
canonical: https://whiteintel.dev/entity/08960acb-4d7f-57d4-ac92-23dcc9abfbf3
json: https://whiteintel.dev/api/public/dossier/08960acb-4d7f-57d4-ac92-23dcc9abfbf3
identifier: sec:0001336503
jurisdiction: US
risk: Low
source: WhiteIntel corporate-ownership graph
---

# KANGO SUJAY

**Type:** Person  
**Jurisdiction:** [US](https://whiteintel.dev/jurisdictions/us)  
**Identifier:** `sec:0001336503`  
**Risk level:** Low  
**Canonical dossier:** https://whiteintel.dev/entity/08960acb-4d7f-57d4-ac92-23dcc9abfbf3  
**Structured JSON / MCP:** https://whiteintel.dev/api/public/dossier/08960acb-4d7f-57d4-ac92-23dcc9abfbf3  

## Ownership & control

### Holdings / subsidiaries

- **Dianthus Therapeutics, Inc. /DE/** (director) — https://whiteintel.dev/entity/6a3adac7-6100-5ac2-87d8-2e2620ec6a23
- **Dianthus Therapeutics, Inc. /DE/** (director) — https://whiteintel.dev/entity/6a3adac7-6100-5ac2-87d8-2e2620ec6a23
- **Dianthus Therapeutics, Inc. /DE/** (director) — https://whiteintel.dev/entity/6a3adac7-6100-5ac2-87d8-2e2620ec6a23
- **LITE STRATEGY, INC.** (director) — https://whiteintel.dev/entity/c3772b71-5536-52ed-890a-0af01a319977
- **DISCOVERY PARTNERS INTERNATIONAL INC** (director) — https://whiteintel.dev/entity/3ae609cf-fccd-58c2-960d-ef36bf02bf22
- **ACCELERON PHARMA INC** (officer) — https://whiteintel.dev/entity/2902d974-49e7-59b3-b374-8b3b3339dcb2
- **DISCOVERY PARTNERS INTERNATIONAL INC** (officer) — https://whiteintel.dev/entity/3ae609cf-fccd-58c2-960d-ef36bf02bf22
- **AVANTOGEN ONCOLOGY, INC.** (director) — https://whiteintel.dev/entity/cca8de16-954e-57c6-8ad3-908c4b3da68e
- **AVANTOGEN ONCOLOGY, INC.** (officer) — https://whiteintel.dev/entity/cca8de16-954e-57c6-8ad3-908c4b3da68e

---

_This is the markdown-for-agents view of the WhiteIntel dossier for **KANGO SUJAY**. Human view: https://whiteintel.dev/entity/08960acb-4d7f-57d4-ac92-23dcc9abfbf3 · Structured JSON: https://whiteintel.dev/api/public/dossier/08960acb-4d7f-57d4-ac92-23dcc9abfbf3._

_Risk levels are heuristic investigative leads, not legal determinations of beneficial ownership. Every claim carries a source; an absent edge means "not yet observed in current sources", not "does not exist"._